SCHEMBL4264371

SCHEMBL4264371

O=C(O)c1cc(F)cc2c1CCCC2

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CXCR5 P32302 2/20 0.45
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 3/20 0.42
HPGD P15428 1/20 0.42
HSD17B10 Q99714 1/20 0.42
RXRA P19793 3/20 0.42
RXRB P28702 2/20 0.42
RXRG P48443 2/20 0.42
PARP1 P09874 2/20 0.40
METAP2 P50579 1/20 0.40
KEAP1 Q14145 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
CYP1A2 P05177 1/20 0.36
XDH P47989 1/20 0.36
SLC22A12 Q96S37 1/20 0.36
FABP3 P05413 1/20 0.36
FABP4 P15090 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12134386 0.96 CXCR5 (0.42) CXCR5KDM4EALDH1A1HPGDHSD17B10
SCHEMBL4260569 0.80 CXCR5 (0.39) CXCR5KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2812292 0.79 ALDH1A1 (0.43) CXCR5KDM4EALDH1A1HPGDHSD17B10
SCHEMBL11731471 0.78 AKR1C4 (0.44) CXCR5KDM4EALDH1A1HPGDHSD17B10
SCHEMBL11727975 0.78 KDM4E (0.43) CXCR5KDM4EALDH1A1HPGDHSD17B10
SCHEMBL30995642 0.78 AKR1C3 (0.44) CXCR5KDM4EALDH1A1HPGDHSD17B10
SCHEMBL19123318 0.78 AKR1C3 (0.44) CXCR5KDM4EALDH1A1HPGDHSD17B10
SCHEMBL30888510 0.78 AKR1C4 (0.44) CXCR5KDM4EALDH1A1HPGDHSD17B10
SCHEMBL11732758 0.74 AKR1C3 (0.44) KDM4EALDH1A1HPGDHSD17B10RXRA
SCHEMBL11729184 0.74 KDM4E (0.43) KDM4EALDH1A1HPGDHSD17B10RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1636221-B1 3-Heterocyclyl-Azetidine compounds useful as NK1/NK2 receptors antagonists ALBIREO AB (SE) 2009-08-12 EP disclosed
US-7402581-B2 Azetidine compounds ALBIREO AB (SE) 2008-07-22 US disclosed
US-20060172988-A1 Azetidine compounds ALBIREO AB (SE) 2006-08-03 US disclosed
EP-1636221-A2 NEW AZETIDINE COMPOUNDS AstraZeneca AB (SE) 2006-03-22 EP disclosed
WO-2004110344-A2 NEW AZETIDINE COMPOUNDS ASTRAZENECA AB (SE) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060172988-A1 Azetidine compounds HRH2, HRH4, HRH1 CXCR5 201/4885KDM4E 1321/4885ALDH1A1 1254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.